CLINICAL TRIALS PROFILE FOR FARESTON

All Clinical Trials for FARESTON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00044291 ↗	Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer	Completed	Intarcia Therapeutics	Phase 3	2002-06-01	The purpose of this study is to determine whether the first line combination hormonal therapy of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer in postmenopausal patients with locally advanced or metastatic breast cancer, and whether the side effects of the combination are different from the side effects of letrozole.
NCT00097344 ↗	The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer	Terminated	Intarcia Therapeutics	Phase 3	2004-12-01	The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another approved drug, letrozole (Femara®), in delaying the growth of breast cancer, and whether the side effects of the combined hormonal therapy are different from the side effects of letrozole.
NCT00267553 ↗	Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer	Terminated	Intarcia Therapeutics	Phase 3	2005-11-01	Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast cancer.
NCT00437359 ↗	Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer	Terminated	Japan Breast Cancer Research Network	Phase 2	2007-05-01	To investigate the benefit of postoperative adjuvant therapy using sequential administration of the hormone, toremifene citrate (TOR) or anastrozole (ANA), after chemotherapy in breast cancer.

Clinical Trial Conditions for FARESTON

Condition Name

Condition Name for FARESTON
Intervention	Trials
Breast Neoplasms	4
Neoplasms, Hormone-Dependent	3
Breast Cancer	3
HER2/Neu Negative	1

Condition MeSH

Condition MeSH for FARESTON
Intervention	Trials
Breast Neoplasms	9
Neoplasms, Hormone-Dependent	3
Neoplasms	3
Breast Carcinoma In Situ	1

Clinical Trial Locations for FARESTON

Trials by Country

Trials by Country for FARESTON
Location	Trials
United States	49
China	22
Canada	4
Ukraine	3
Russian Federation	3

Trials by US State

Trials by US State for FARESTON
Location	Trials
Washington	4
Virginia	3
Texas	3
Missouri	3
Michigan	3

Clinical Trial Progress for FARESTON

Clinical Trial Phase

Clinical Trial Phase for FARESTON
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	6
Phase 2	1

Clinical Trial Status

Clinical Trial Status for FARESTON
Clinical Trial Phase	Trials
Terminated	3
Recruiting	2
Completed	2

Clinical Trial Sponsors for FARESTON

Sponsor Name

Sponsor Name for FARESTON
Sponsor	Trials
Intarcia Therapeutics	3
Fudan University	2
Union hospital of Fujian Medical University	1

Sponsor Type

Sponsor Type for FARESTON
Sponsor	Trials
Other	28
Industry	3
NIH	1